Skip to main content
Fig. 6 | World Journal of Surgical Oncology

Fig. 6

From: Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16

Fig. 6

Serum selenium content in prostate cancer patients is correlated with clinical prognosis. a Comparing the serum selenium content among AIPC, ADPC, and healthy control groups. b Determination of the correlation between serum selenium content and serum miR-16 expressions. The c overall survival and d disease-free survival of prostate cancer patients with different serum selenium level. Solid line: serum selenium level high group; dotted line: serum selenium level low group

Back to article page